153 related articles for article (PubMed ID: 24171174)
1. The use of multidimensional data to identify the molecular biomarker for pancreatic ductal adenocarcinoma.
Zhuang L; Qi Y; Wu Y; Liu N; Fu Y
Biomed Res Int; 2013; 2013():798054. PubMed ID: 24171174
[TBL] [Abstract][Full Text] [Related]
2. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatic Analysis Suggests That Three Hub Genes May Be a Vital Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.
Chang X; Yang MF; Fan W; Wang LS; Yao J; Li ZS; Li DF
J Comput Biol; 2020 Nov; 27(11):1595-1609. PubMed ID: 32216644
[TBL] [Abstract][Full Text] [Related]
4. Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis.
Shang M; Zhang L; Chen X; Zheng S
Discov Med; 2019 Sep; 28(153):159-172. PubMed ID: 31926587
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer survival analysis defines a signature that predicts outcome.
Raman P; Maddipati R; Lim KH; Tozeren A
PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
[TBL] [Abstract][Full Text] [Related]
6. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction.
Tan Z; Lei Y; Xu J; Shi S; Hua J; Zhang B; Meng Q; Liu J; Zhang Y; Wei M; Yu X; Liang C
Aging (Albany NY); 2020 Nov; 12(23):24228-24241. PubMed ID: 33226369
[TBL] [Abstract][Full Text] [Related]
7. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
8. Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.
Liu XG; Xu H; Chen M; Tan XY; Chen XF; Yang YG; Lin MZ; Liu GH; Liang XL; Qian YB; Yuan GJ; Chen MQ; Li WT; Miao HL; Li MY; Liao XW; Dai W; Chen NP
Cancer Med; 2020 Mar; 9(6):2062-2076. PubMed ID: 31991068
[TBL] [Abstract][Full Text] [Related]
9. Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms.
Zhou X; Liao X; Wang X; Huang K; Yang C; Yu T; Han C; Zhu G; Su H; Han Q; Chen Z; Huang J; Gong Y; Ruan G; Ye X; Peng T
Cancer Med; 2020 Feb; 9(3):859-871. PubMed ID: 31808619
[TBL] [Abstract][Full Text] [Related]
10. Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis.
You L; Wang J; Zhang F; Zhang J; Tao H; Zheng X; Hu Y
Mol Med Rep; 2019 Jan; 19(1):441-451. PubMed ID: 30483731
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
12. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
13. Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma.
Song J; Xu Q; Zhang H; Yin X; Zhu C; Zhao K; Zhu J
J Cell Biochem; 2018 Jun; 119(6):4559-4569. PubMed ID: 29239017
[TBL] [Abstract][Full Text] [Related]
14. Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis.
Rajamani D; Bhasin MK
Genome Med; 2016 May; 8(1):38. PubMed ID: 27137215
[TBL] [Abstract][Full Text] [Related]
15. Differential MicroRNA Expression Profiles as Potential Biomarkers for Pancreatic Ductal Adenocarcinoma.
Zhu Y; Wang J; Wang F; Yan Z; Liu G; Ma Y; Zhu W; Li Y; Xie L; Bazhin AV; Guo X
Biochemistry (Mosc); 2019 May; 84(5):575-582. PubMed ID: 31234772
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis of gene expression profiles reveals specific signaling pathways associated with pancreatic duct adenocarcinoma.
Li J; Tan W; Peng L; Zhang J; Huang X; Cui Q; Zheng J; Tan W; Wu C; Lin D
Cancer Commun (Lond); 2018 Apr; 38(1):13. PubMed ID: 29764514
[TBL] [Abstract][Full Text] [Related]
17. miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.
Tesfaye AA; Azmi AS; Philip PA
Am J Pathol; 2019 Jan; 189(1):58-70. PubMed ID: 30558723
[TBL] [Abstract][Full Text] [Related]
18. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.
Martinez-Useros J; Georgiev-Hristov T; Fernández-Aceñero MJ; Borrero-Palacios A; Indacochea A; Guerrero S; Li W; Cebrián A; Gómez Del Pulgar T; Puime-Otin A; Del Puerto-Nevado L; Rodríguez-Remírez M; Pérez N; Celdrán A; Gebauer F; Garcia-Foncillas J
PLoS One; 2017; 12(8):e0182044. PubMed ID: 28763470
[TBL] [Abstract][Full Text] [Related]
19. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
[TBL] [Abstract][Full Text] [Related]
20. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.
Cote GA; Gore AJ; McElyea SD; Heathers LE; Xu H; Sherman S; Korc M
Am J Gastroenterol; 2014 Dec; 109(12):1942-52. PubMed ID: 25350767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
